BiomX Q3 2026 Earnings Date & Estimates

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial microorganisms. The company’s platform uses naturally occurring bacteriophages, or viruses that selectively infect and destroy specific bacteria, to address diseases associated with the microbiome.

BiomX has focused its research and development programs on conditions including cystic fibrosis and inflammatory bowel disease. Its pipeline has included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa in the lungs of people with cystic fibrosis, and BX211, an investigational therapy intended to target disease-associated bacteria in the gastrointestinal tract.

Founded in Israel and with roots connected to research conducted at the Weizmann Institute of Science, BiomX has operated as a publicly traded biotechnology company since completing a business combination in 2019. The company has conducted development activities through operations in Israel and the United States. As a clinical-stage company, BiomX’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established for commercial use.